| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Devices and Research
News
|
Press Release:
Nuclear Medicine Leader Dr. M. Donald Blaufox Leads Cell Point Cancer Diagnostic Phase 2/3 Trial
CENTENNIAL, Colo., Feb. 10 (SEND2PRESS NEWSWIRE) -- Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of 99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway.99mTc-EC-G is the company's cancer diagnostic imaging agent, an acronym for 99mTechnetium-EthylenediCysteine-Glucosamine. "We are honored to have the support and cooperation from a physician with the recognized stature of Dr. Blaufox," said Greg Colip, Cell>Point CEO. "He's a founder and leader in nuclear medicine." Blaufox will present clinical trial findings at select upcoming medical conferences. Blaufox is founding Chairman of the Department of Nuclear Medicine at Albert Einstein College of Medicine and Montefiore Medical Center. Among his many other credentials are: * Former chairman and lifetime member American Board of Nuclear Medicine * Principal investigator Hypertension Detection and Follow-up program (Lasker Award recipient) * Clinical trials review committee National Heart, Lung and Blood Institute * 293 peer-review articles and chapters * 25 medical texts * Editorial board six journals * Co-editor Seminars in Nuclear Medicine, Yearbook of Nuclear Medicine * Numerous named lectures and international awards * Honorary Professor of Medicine, Shanxi University School of Medicine, Taiyuan, China * Founding chairman Nuclear Medicine Section, New York Academy of Medicine. Montefiore Medical Center is one of six clinical trial sites for the 99mTc-EC-G cancer trial. Others are John Hopkins University, Mayo Clinic, Baptist Health South Florida, Decatur Memorial Hospital, and British Columbia Medical Center in North Vancouver, Canada. Blaufox is also principal investigator of the Montefiore site. The Phase 2/3 clinical trial compares 99mTc-EC-G (administered and then imaged with a SPECT camera) to 18F-FDG (administered and then imaged with a PET camera) in the evaluation of patients with non-small cell lung cancer. More information on the trial can be found at www.clinicaltrials.gov. Trial identifier is NCT00865319. More information on 99mTc-EC-G can be found at the Cell>Point Website (www.cellpointweb.com) under Technology\Pipeline. 18F-FDG is FluoroDeoxyGlucose. Used in the medical imaging modality Positron Emission Tomography (PET), it is the current standard in diagnosing, staging, and monitoring treatment of cancers. SPECT is Single Photon Emission Computed Tomography. SPECT cameras are 25-fold more prevalent than, and one-quarter the cost of, PET cameras. Radiation from a 99mTc-EC-G SPECT procedure is as much as 75 percent less than that of an 18F-FDG PET procedure. About Cell>Point: Cell>Point is a clinical-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart, and other diseases. Cell>Point has exclusive license to five drug-development platforms, all from The University of Texas M. D. Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point's drug candidates, recent press releases, and patents and patent filings can be obtained through its Website at www.cellpointweb.com. The company is headquartered in Centennial, Colo., and has additional offices in San Francisco and Houston.
NEWS SOURCE: Cell Point LLC
Send2Press® is the originating wire service for this story. Terms of Use. © Cell Point LLC. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Cell Point LLC), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Cell Point LLC.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Cell Point LLC : » Nuclear Medicine Leader Dr. M. Donald Blaufox Leads Cell Point Cancer Diagnostic Phase 2/3 Trial
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Nuclear Medicine Leader Dr. M. Donald Blaufox Leads Cell Point Cancer Diagnostic Phase 2/3 Trial, Cell Point LLC, cancer diagnostic imaging agent, M Donald Blaufox, CEO Greg Colip, clinical trial identifier NCT00865319, nuclear medicine, Colorado business, 99mTc-EC-G, 99mTechnetium EthylenediCysteine Glucosamine, universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart, and other diseases, press release, Feb 10, 2010. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 3548 times (3 today, 7 this week, 26 this month, 102 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)